Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
SURPASS-4 Investigators
Research output: Contribution to journal › Article › peer-review
328Scopus
citations
Fingerprint
Dive into the research topics of 'Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial'. Together they form a unique fingerprint.